Mihaela Campan, 654225 Via Arbolada UNIT 582, Los Angeles, CA 90042
Mihaela Campan Phones & Addresses
Los Angeles, CA
Morongo Valley, CA
Downey, CA
Mentions for Mihaela Campan
Publications & IP owners
Us Patents
High Throughput Methods Comprising Analysis Of Repetitive Element Dna Methylation
US Patent:
8642263, Feb 4, 2014
Filed:
Nov 10, 2005
Appl. No.:
11/719033
Inventors:
Peter W. Laird - South Pasadena CA, US
Daniel J. Weisenberger - Playa Del Rey CA, US
Mihaela Campan - Los Angeles CA, US
Tifany I. Long - Chino CA, US
Daniel J. Weisenberger - Playa Del Rey CA, US
Mihaela Campan - Los Angeles CA, US
Tifany I. Long - Chino CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 612, 435 61, 435 611
Abstract:
Preferred aspects provide novel high-throughput, sensitive methods (e. g. , real-time PCR-based (MethyLight™) reactions) for detection and/or measurement of global genomic 5-methylcytosine content, based on measurement of DNA methylation of Alu, LINE-1 repetitive sequences, and the chromosome 1 centromeric satellite alpha and juxtacentromeric satellite 2 repeat sequences. Additional aspects provide sensitive methods for determining the amount of a DNA (e. g. , in formalin-fixed, paraffin-embedded tissues). Combined (mean) use of Alu and Sat2 repeat methylation measurements provides for a surprisingly close correlation with global genomic 5-methylcytosine content measurements obtained by HPLC. Methylation of Alu repeats was determined to be closely associated with HPLC-based global methylation levels, as was methylation of satellite 2 and LINE-1 global genomic 5-methylcytosine content. The assays provide surrogate markers for global genomic 5-methylcytosine content analyzes, and have substantial utility for high-throughput and population-based studies (e. g.
Dna Methylation Analysis By Digital Bisulfite Genomic Sequencing And Digital Methylight
US Patent:
2008025, Oct 16, 2008
Filed:
Apr 14, 2008
Appl. No.:
12/102783
Inventors:
Peter W. Laird - South Pasadena CA, US
Binh N. Trinh - Alhambra CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberger - Playa Del Rey CA, US
Binh N. Trinh - Alhambra CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberger - Playa Del Rey CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Provided are novel sensitive methylation assays referred to herein as Digital MethyLight, comprising stochastically distributing and compartmentalizing bisulfite-treated genomic DNA over multiple PCR reaction wells for detection of individually methylated DNA molecules in a large background of unmethylated DNA. Digital Bisulfite Genomic DNA Sequencing methods are also provided for high-resolution DNA methylation information without subcloning. Background signal and PCR contaminants are diluted, while the ratio of primer to methylated template DNA is kept high. Preferably, biological fluid (e.g., urine, blood-based (e.g., plasma and/or serum)) samples are analyzed for cancer diagnosis, prognosis and surveillance. Multiplexed PCR formats may be implemented to enhance when using small DNA amounts. Compositions and methods for diagnosis and/or prognosis of breast cancer, comprising the use of FOXE1, CLDN5 and/or RUNX3 gene markers are also provided (SEQ ID NOS: 17, 16 and 18, respectively for respective CpG island sequences), and in preferred embodiments plasma or serum samples are used.
High Throughput Method Of Dna Methylation Haplotyping
US Patent:
2008028, Nov 20, 2008
Filed:
Nov 22, 2006
Appl. No.:
12/094952
Inventors:
Mihaela Campan - Los Angeles CA, US
Peter W. Laird - South Pasadena CA, US
Allen S. Yang - Valencia CA, US
Peter W. Laird - South Pasadena CA, US
Allen S. Yang - Valencia CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Particular aspects provide novel, high-throughput methods to quantify DNA methylation (e.g., at a single-base resolution) in an allele-specific manner. The methods comprise use of an allele-specific sequence polymorphism (e.g., allele-specific single nucleotide polymorphism; SNP) in sufficient proximity to a CpG methylation site to provide for distinguishing the methylation levels between two alleles. In particular aspects, after bisulfite modification, the genomic DNA region is PCR-amplified, and the product subjected to allele-specific pyrosequencing, and the percentage of methylation determined based on the percentage of cytosine to thymidine conversion. In further embodiments, MethyLight™ is used after bisulfite treatment. The inventive methodology has, for example, substantial utility for affording quantitative analyses in the regulation of analyses of X-inactivation, the allele-specific expression of genes (e.g., in the immune system) and junk DNA, etc., and in classifying an individual as to whether they have loss of imprinting (LOI).
Dna Methylation Markers Associated With The Cpg Island Methylator Phenotype (Cimp) In Human Colorectal Cancer
US Patent:
2009005, Feb 26, 2009
Filed:
May 2, 2006
Appl. No.:
11/913535
Inventors:
Peter W. Laird - South Pasadena CA, US
KImberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberg - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US
KImberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberg - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US
Assignee:
University of Southern California - Los Angles CA
International Classification:
C12Q 1/68
C12Q 1/02
G01N 33/53
C07H 21/00
C12Q 1/02
G01N 33/53
C07H 21/00
US Classification:
435 6, 435 29, 435 71, 435 792, 536 2431
Abstract:
Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).
Dna Methylation Markers Associated With The Cpg Island Methylator Phenotype (Cimp) In Human Colorectal Cancer
US Patent:
2012021, Aug 30, 2012
Filed:
Feb 3, 2012
Appl. No.:
13/366192
Inventors:
Peter W. Laird - South Pasadena CA, US
Kimberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberger - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US
Kimberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberger - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12Q 1/68
C07H 21/04
G01N 33/574
C07H 21/04
G01N 33/574
US Classification:
435 611, 436501, 536 231
Abstract:
Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).
Dna Methylation Markers Associated With The Cpg Island Methylator Phenotype (Cimp) In Human Colorectal Cancer
US Patent:
2016028, Oct 6, 2016
Filed:
Mar 9, 2016
Appl. No.:
15/065782
Inventors:
- Los Angeles CA, US
Kimberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberger - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US
Kimberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberger - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US
International Classification:
C12Q 1/68
Abstract:
Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation, and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread, and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms, and history of hormonal use).
Accurate In Vitro Copying Of Dna Methylation
US Patent:
2016013, May 12, 2016
Filed:
Oct 30, 2015
Appl. No.:
14/929234
Inventors:
Jinkeng Asong - Hanahan SC, US
Mihaela Campan - Los Angeles CA, US
Po-Han Chen - Temple City CA, US
Crystal N. Marconett - Sun Valley CA, US
Ian Stuart Haworth - Santa Monica CA, US
Mihaela Campan - Los Angeles CA, US
Po-Han Chen - Temple City CA, US
Crystal N. Marconett - Sun Valley CA, US
Ian Stuart Haworth - Santa Monica CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12Q 1/68
Abstract:
A method of copying a methylated nucleic acid molecule is provided. The method includes copying a nucleic acid molecule into a plurality of nucleic acid molecules; and contacting the plurality of nucleic acid molecules with a DNA methyltransferase enzyme and an E3 ubiquitin ligase. The method results in the copying of the methylated nucleic acid molecule.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.